Loading

Minutia

May 06, 2024
Session
Company Description: Minutia is developing a regenerative medicine platform that improves safety and success outcomes of transplanted cells, our first therapy is a functional cure for Type 1 and Insulin Dependent Type 2 Diabetes with a simple outpatient procedure. We have already successfully demonstrated our out-patient transplant procedure in a PI-led Phase 1/2 clinical trial at UCSF, and are progressing our nanoparticle instrumented stem cell platform to enable safety and personalization across the broader cell therapy market.

Minutia
View all SUS 2024

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS